ELECTROMED INC (ELMD) Stock Price, Forecast & Analysis

NYSEARCA:ELMD • US2854091087

24.1 USD
+0.4 (+1.69%)
Last: Mar 2, 2026, 08:15 PM

ELMD Key Statistics, Chart & Performance

Key Statistics
Market Cap200.99M
Revenue(TTM)64.00M
Net Income(TTM)8.20M
Shares8.34M
Float6.56M
52 Week High30.73
52 Week Low17.73
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)1.03
PE23.4
Fwd PE17.87
Earnings (Next)05-11
IPO2010-08-13
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
ELMD short term performance overview.The bars show the price performance of ELMD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15

ELMD long term performance overview.The bars show the price performance of ELMD in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40 60 80 100

The current stock price of ELMD is 24.1 USD. In the past month the price decreased by -19.32%. In the past year, price decreased by -5.23%.

ELECTROMED INC / ELMD Daily stock chart

ELMD Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
ELMD Full Technical Analysis Report

ELMD Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to ELMD. ELMD scores excellent points on both the profitability and health parts. This is a solid base for a good stock.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ELMD Full Fundamental Analysis Report

ELMD Financial Highlights

Over the last trailing twelve months ELMD reported a non-GAAP Earnings per Share(EPS) of 1.03. The EPS increased by 37.33% compared to the year before.


Industry RankSector Rank
PM (TTM) 12.38%
ROA 15.29%
ROE 18.32%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%45.45%
Sales Q2Q%16.25%
EPS 1Y (TTM)37.33%
Revenue 1Y (TTM)16.97%
ELMD financials

ELMD Forecast & Estimates

10 analysts have analysed ELMD and the average price target is 37.4 USD. This implies a price increase of 55.19% is expected in the next year compared to the current price of 24.1.

For the next year, analysts expect an EPS growth of 28.75% and a revenue growth 14.79% for ELMD


Analysts
Analysts82
Price Target37.4 (55.19%)
EPS Next Y28.75%
Revenue Next Year14.79%
ELMD Analyst EstimatesELMD Analyst Ratings

ELMD Ownership

Ownership
Inst Owners51.92%
Ins Owners8.11%
Short Float %2.65%
Short Ratio2.63
ELMD Ownership

ELMD Latest News, Press Relases and Analysis

All ELMD news

ELMD Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.87202.318B
ISRG INTUITIVE SURGICAL INC48.55178.812B
SYK STRYKER CORP25.6148.172B
BSX BOSTON SCIENTIFIC CORP21.76113.97B
IDXX IDEXX LABORATORIES INC42.9752.44B
BDX BECTON DICKINSON AND CO11.250.281B
EW EDWARDS LIFESCIENCES CORP29.3250.178B
GEHC GE HEALTHCARE TECHNOLOGY15.9638.406B
RMD RESMED INC20.9637.332B
DXCM DEXCOM INC29.2228.639B

About ELMD

Company Profile

ELMD logo image Electromed, Inc. engages in the development, manufacture, marketing, and sale of medical equipment. The company is headquartered in New Prague, Minnesota and currently employs 177 full-time employees. The company went IPO on 2010-08-13. The company applies High Frequency Chest Wall Oscillation (HFCWO) technologies in pulmonary care for patients of all ages. The SmartVest Clearway System consists of an inflatable therapy garment, a programmable air pulse generator and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall. The SmartVest Clearway is designed for comfort and convenience, so patients can readily fit therapy into their daily routines. The SmartVest System is primarily prescribed for patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and amyotrophic lateral sclerosis. The company also markets the Single Patient Use (SPU) SmartVest and SmartVest Wrap to health care providers in the acute care setting.

Company Info

ELECTROMED INC

500 Sixth Avenue Nw

New Prague MINNESOTA 56071 US

CEO: Kathleen S. Skarvan

Employees: 174

ELMD Company Website

ELMD Investor Relations

Phone: 19527589299

ELECTROMED INC / ELMD FAQ

What does ELECTROMED INC do?

Electromed, Inc. engages in the development, manufacture, marketing, and sale of medical equipment. The company is headquartered in New Prague, Minnesota and currently employs 177 full-time employees. The company went IPO on 2010-08-13. The company applies High Frequency Chest Wall Oscillation (HFCWO) technologies in pulmonary care for patients of all ages. The SmartVest Clearway System consists of an inflatable therapy garment, a programmable air pulse generator and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall. The SmartVest Clearway is designed for comfort and convenience, so patients can readily fit therapy into their daily routines. The SmartVest System is primarily prescribed for patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and amyotrophic lateral sclerosis. The company also markets the Single Patient Use (SPU) SmartVest and SmartVest Wrap to health care providers in the acute care setting.


What is the current price of ELMD stock?

The current stock price of ELMD is 24.1 USD. The price increased by 1.69% in the last trading session.


Does ELECTROMED INC pay dividends?

ELMD does not pay a dividend.


How is the ChartMill rating for ELECTROMED INC?

ELMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.


What is the analyst forecast for ELMD stock?

10 analysts have analysed ELMD and the average price target is 37.4 USD. This implies a price increase of 55.19% is expected in the next year compared to the current price of 24.1.


What is the expected growth for ELMD stock?

The Revenue of ELECTROMED INC (ELMD) is expected to grow by 14.79% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.